antibody

Rabbit anti Phospho- JAK2 (pTyr 1007/1008)Biotinylated

MBS462108

0.1 mg

385 USD

polyclonal

rabbit

biotin

human, mouse, rat

western blot, ELISA, immunohistochemistry

Antibody

Rabbit anti Phospho- JAK2 (pTyr 1007/1008)Biotinylated

JAK2 (pY1007/Y1008) (Biotinylated)

Rabbit anti-Phospho-JAK2 (pY1007/1008); Biotinylated; Biotin-conjugated Rabbit anti phosphospecifici-Janus Kinase 2

tyrosine-protein kinase JAK2; Tyrosine-protein kinase JAK2; tyrosine-protein kinase JAK2; JAK-2; OTTHUMP00000021024; Janus kinase 2 (a protein tyrosine kinase); Janus kinase 2; Janus kinase 2

JAK2 (pY1007/Y1008) (Biotinylated)

JAK2; JAK2; JTK10

JAK2_HUMAN

Rabbit

Human, Rat, Mouse

This biotinylated antibody recognizes JAK2 with dual phosphorylated sites of Tyr1007/1008. It does not crossreact with non-phosphospecific peptide.

The Rabbit IgG is purified by site-modified Epitope Affinity Purification.

This affinity purified antibody is supplied in sterile Tris-buffered saline (pH7.2) containing antibody stabilizer

Size: 100 ug/200 ul

The antibodies are stable for 12 months from date of receipt when stored at -20 degree C to -70 degree C. The antibodies can be stored at 2 degree C-8 degree C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.

ELISA, Western Blot, Immunohistochemistry

Western Blot: 0.1-1 ug/ml. ELISA: 0.01-0.1 ug/ml. Immunoprecipitation: 2-5 ug/ml. Immunohistochemistry: 1-5 ug/ml

Antigen Preparation: A synthetic peptide surrounding to the epitope -EYYK- with dual phosphorylation sites at Tyr1008 and Tyr1009 of JAK2 from human, mouse and rat origins.

Positive Control: GH stimulated mouse liver. Cellular Location: Cytoplasmic

The Janus tyrosine kinase family is consists of four members, JAK1, JAK2, JAK3 and Tyk2. Upon the cytokine ligand binding to its the receptors, the dimerization of the receptors occurs followed by phosphorylation of the receptors. The phosphorylation of receptors recruites the tyrosine kinase physically associated to the dimerized receptors, and the phosphorylate the kinase, thus activates the signal transducer and activator of thranscription (STAT1, 3, 5) and the other signal proteins

Yogev,O., et al. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J. Biol. Chem. 278 (52), 52021-52031 (2003)

4826776

NP_004963.1

NM_004972.2

O60674

120 kDa (130kDa)

Adipocytokine Signaling Pathway (83093); Adipocytokine Signaling Pathway (505); CXCR4-mediated Signaling Events Pathway (137910); Chemokine Signaling Pathway (99051); Chemokine Signaling Pathway (96864); Cholinergic Synapse Pathway (217716); Cytokine Signaling In Immune System Pathway (366171); Delta-Notch Signaling Pathway (198879); EGFR1 Signaling Pathway (198782); EPO Receptor Signaling Pathway (198882)

This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq]

Function: Non-receptor tyrosine kinase involved in various processes such as cell cycle progression, apoptosis, mitotic recombination, genetic instability and histone modifications. In the cytoplasm, plays a pivotal role in signal transduction via its association with cytokine receptors, which constitutes an initiating step in signaling for many members of the cytokine receptor superfamily including the receptors for growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), granulocyte-macrophage colony-stimulating factor (CSF2), thrombopoietin (THPO) and multiple interleukins. Following stimulation with erythropoietin (EPO) during erythropoiesis, it is autophosphorylated and activated, leading to its association with erythropoietin receptor (EPOR) and tyrosine phosphorylation of residues in the EPOR cytoplasmic domain. Also involved in promoting the localization of EPOR to the plasma membrane. Also acts downstream of some G-protein coupled receptors. Plays a role in the control of body weight. By similarity. Mediates angiotensin-2-induced ARHGEF1 phosphorylation. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin. Ref.7 Ref.14 Ref.16. Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. Enzyme regulation: Regulated by autophosphorylation, can both activate or decrease activity. By similarity. Heme regulates its activity by enhancing the phosphorylation on Tyr-1007 and Tyr-1008. Ref.15. Subunit structure: Interacts with EPOR, SIRPA and SH2B1. By similarity. Interacts with IL23R, SKB1 and STAM2. Ref.5 Ref.6 Ref.7. Subcellular location: Endomembrane system; Peripheral membrane protein. By similarity. Nucleus Ref.14. Tissue specificity: Expressed in blood, bone marrow and lymph node. Ref.12. Domain: Possesses 2 protein kinase domains. The second one probably contains the catalytic domain, while the presence of slight differences suggest a different role for protein kinase 1. Post-translational modification: Autophosphorylated, leading to regulate its activity. Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in response to EPO down-regulates its kinase activity. Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to growth hormone (GH) are required for maximal kinase activity. By similarity. Ref.13 Ref.17. Involvement in disease: Note=Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome (BCS) [. MIM:600880]. It is a syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.Defects in JAK2 are a cause of polycythemia vera (PV) [. MIM:263300]. A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. Ref.18 Ref.21 Ref.22 Ref.25Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [. MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. Ref.3 Ref.20Defects in JAK2 are a cause of myelofibrosis (MYELOF) [. MIM:254450]. Myelofibrosis is a disorder characterized by replacement of the bone marrow by fibrous tissue, occurring in association with a myeloproliferative disorder. Clinical manifestations may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [. MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Ref.24. Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.Contains 1 FERM domain.Contains 1 protein kinase domain.Contains 1 SH2 domain.

0.1 mg

385 USD